ETF Foundry Research (hypothetical) · rebalanced monthly
Every other metric on this page is the long-shortstrategy, which needs a short book. This fund is the long leg alone, so these are the figures for what it actually holds. The bottom-bucket number is that basket’s own return — not short P&L.
Gross of the placeholder expense ratio and trading costs · not investor results
Every constituent of the long leg — sort, search or filter by sector
| Ticker | Company | Sector | Market cap | Weight |
|---|---|---|---|---|
1MRNA | MODERNA INC | Healthcare | $93.61B | 22.05% |
2BDX | BECTON DICKINSON & CO | Healthcare | $58.76B | 13.84% |
3TEVA | TEVA PHARMACEUTICAL INDUSTRIES LTD | Healthcare | $50.93B | 12.00% |
4INCY | INCYTE CORP | Healthcare | $24.81B | 5.84% |
5VTRS | VIATRIS INC | Healthcare | $23.70B | 5.58% |
6EXEL | EXELIXIS INC | Healthcare | $17.04B | 4.01% |
7CRL | CHARLES RIVER LABORATORIES INTERNATIONAL INC | Healthcare | $16.33B | 3.85% |
8HALO | HALOZYME THERAPEUTICS INC | Healthcare | $11.48B | 2.70% |
9BRKR | BRUKER CORP | Healthcare | $9.21B | 2.17% |
10TXG | 10X GENOMICS INC | Healthcare | $7.77B | 1.83% |
11KOD | KODIAK SCIENCES INC | Healthcare | $6.80B | 1.60% |
12TFX | TELEFLEX INC | Healthcare | $6.07B | 1.43% |
13ERAS | ERASCA INC | Healthcare | $5.52B | 1.30% |
14ADPT | ADAPTIVE BIOTECHNOLOGIES CORP | Healthcare | $4.77B | 1.12% |
15ICUI | ICU MEDICAL INC | Healthcare | $4.43B | 1.04% |
16TNGX | TANGO THERAPEUTICS INC | Healthcare | $4.21B | 0.99% |
17CDNA | CAREDX INC | Healthcare | $4.19B | 0.99% |
18CRSP | CRISPR THERAPEUTICS AG | Healthcare | $4.13B | 0.97% |
19RLAY | RELAY THERAPEUTICS INC | Healthcare | $3.99B | 0.94% |
20ABCL | ABCELLERA BIOLOGICS INC | Healthcare | $3.80B | 0.89% |
21SGRY | SURGERY PARTNERS INC | Healthcare | $3.48B | 0.82% |
22DYN | DYNE THERAPEUTICS INC | Healthcare | $3.19B | 0.75% |
23VCEL | VERICEL CORP | Healthcare | $2.93B | 0.69% |
24BEAM | BEAM THERAPEUTICS INC | Healthcare | $2.49B | 0.59% |
25NEOG | NEOGEN CORP | Healthcare | $2.44B | 0.58% |
26SDGR | SCHRODINGER INC | Healthcare | $2.32B | 0.55% |
27PRGO | PERRIGO CO PLC | Healthcare | $2.25B | 0.53% |
28AUPH | AURINIA PHARMACEUTICALS INC | Healthcare | $2.17B | 0.51% |
29BKD | BROOKDALE SENIOR LIVING INC | Healthcare | $2.14B | 0.51% |
30VIR | VIR BIOTECHNOLOGY INC | Healthcare | $2.08B | 0.49% |
31ESTA | ESTABLISHMENT LABS HOLDINGS INC | Healthcare | $2.05B | 0.48% |
32MRVI | MARAVAI LIFESCIENCES HOLDINGS INC | Healthcare | $2.00B | 0.47% |
33BFLY | BUTTERFLY NETWORK INC | Healthcare | $1.78B | 0.42% |
34ETON | ETON PHARMACEUTICALS INC | Healthcare | $1.77B | 0.42% |
35SRPT | SAREPTA THERAPEUTICS INC | Healthcare | $1.72B | 0.40% |
36ABSI | ABSCI CORP | Healthcare | $1.57B | 0.37% |
37PCRX | PACIRA BIOSCIENCES INC | Healthcare | $1.46B | 0.34% |
38NVAX | NOVAVAX INC | Healthcare | $1.45B | 0.34% |
39AMN | AMN HEALTHCARE SERVICES INC | Healthcare | $1.44B | 0.34% |
40STAA | STAAR SURGICAL CO | Healthcare | $1.34B | 0.32% |
41OMER | OMEROS CORP | Healthcare | $1.30B | 0.31% |
42INBX | INHIBRX BIOSCIENCES INC | Healthcare | $1.29B | 0.30% |
43INNV | INNOVAGE HOLDING CORP | Healthcare | $1.28B | 0.30% |
44NKTR | NEKTAR THERAPEUTICS | Healthcare | $1.27B | 0.30% |
45ANRO | ALTO NEUROSCIENCE INC | Healthcare | $1.23B | 0.29% |
46BVS | BIOVENTUS INC | Healthcare | $915M | 0.22% |
47MGTX | MEIRAGTX HOLDINGS PLC | Healthcare | $844M | 0.20% |
48SLDB | SOLID BIOSCIENCES INC | Healthcare | $781M | 0.18% |
49AURA | AURA BIOSCIENCES INC | Healthcare | $740M | 0.17% |
50FDMT | 4D MOLECULAR THERAPEUTICS INC | Healthcare | $669M | 0.16% |
51DNA | GINKGO BIOWORKS HOLDINGS INC | Healthcare | $663M | 0.16% |
52SRZN | SURROZEN INC | Healthcare | $604M | 0.14% |
53NRC | NRC HEALTH | Healthcare | $565M | 0.13% |
54MYGN | MYRIAD GENETICS INC | Healthcare | $545M | 0.13% |
55RGNX | REGENXBIO INC | Healthcare | $531M | 0.13% |
56TKNO | ALPHA TEKNOVA INC | Healthcare | $522M | 0.12% |
57RCEL | AVITA MEDICAL INC | Healthcare | $509M | 0.12% |
58ANGO | ANGIODYNAMICS INC | Healthcare | $504M | 0.12% |
59NPCE | NEUROPACE INC | Healthcare | $413M | 0.10% |
60LYEL | LYELL IMMUNOPHARMA INC | Healthcare | $385M | 0.09% |
61PEPG | PEPGEN INC | Healthcare | $349M | 0.08% |
62VMD | VIEMED HEALTHCARE INC | Healthcare | $345M | 0.08% |
63MPLT | MAPLIGHT THERAPEUTICS INC | Healthcare | $328M | 0.08% |
64ENTA | ENANTA PHARMACEUTICALS INC | Healthcare | $326M | 0.08% |
65AGEN | AGENUS INC | Healthcare | $311M | 0.07% |
66EBS | EMERGENT BIOSOLUTIONS INC | Healthcare | $303M | 0.07% |
67INFU | INFUSYSTEM HOLDINGS INC | Healthcare | $296M | 0.07% |
68FTH | FAETH THERAPEUTICS INC | Healthcare | $275M | 0.06% |
69QTTB | Q32 BIO INC | Healthcare | $264M | 0.06% |
70ARCT | ARCTURUS THERAPEUTICS HOLDINGS INC | Healthcare | $243M | 0.06% |
71SPOK | SPOK HOLDINGS INC | Healthcare | $243M | 0.06% |
72LFCR | LIFECORE BIOMEDICAL INC | Healthcare | $243M | 0.06% |
73DTIL | PRECISION BIOSCIENCES INC | Healthcare | $225M | 0.05% |
74AMWL | AMERICAN WELL CORP | Healthcare | $207M | 0.05% |
75TRDA | ENTRADA THERAPEUTICS INC | Healthcare | $202M | 0.05% |
76KRRO | KORRO BIO INC | Healthcare | $196M | 0.05% |
77STRO | SUTRO BIOPHARMA INC | Healthcare | $159M | 0.04% |
78INGN | INOGEN INC | Healthcare | $146M | 0.03% |
79CUE | CUE BIOPHARMA INC | Healthcare | $127M | 0.03% |
80SPRB | SPRUCE BIOSCIENCES INC | Healthcare | $123M | 0.03% |
81CPIX | CUMBERLAND PHARMACEUTICALS INC | Healthcare | $99M | 0.02% |
82ICCC | IMMUCELL CORP | Healthcare | $93M | 0.02% |
83ATRA | ATARA BIOTHERAPEUTICS INC | Healthcare | $81M | 0.02% |
84POCI | PRECISION OPTICS CORPORATION INC | Healthcare | $55M | 0.01% |
85COCH | ENVOY MEDICAL INC | Healthcare | $53M | 0.01% |
86ELOX | ELOXX PHARMACEUTICALS INC | Healthcare | $52M | 0.01% |
Full long-leg book as of November 2026 · cap-weighted · total market cap $424.54B. Hypothetical model holdings — not a registered fund’s portfolio.
Size × value map of the long-leg book
Share of long-leg capital by market cap × book-to-market, using terciles of the 465-name universe at November 2026. Rows: Large ≥ $4.2B, Small < $1.1B. Columns: Value ≥ 0.67, Growth < 0.36 B/M. The dot marks the capital-weighted centroid of the book — 90% toward Large, 82% toward Growth. +10% unclassified (14 missing size/value). Hypothetical holdings — descriptive, not realized P&L.
Capital-weighted centroid of the long leg, December 1998 → November 2026; the right-hand end is the same value as the box’s dot. 86 names now. The faded start covers early months with a much thinner universe. Hypothetical holdings — descriptive, not P&L.
How this book measures against the concentration and liquidity rules — as implemented here
The constraint checks couldn’t be loaded. The service didn’t respond, so this is a gap in what we could fetch — not a statement about the factor.
Reloading the page usually resolves it.
Whether this long-only book is subject to the VaR tests at all
This assessment describes the long-only book this fund holds — the top bucket only.
This fund QUALIFIES for the limited-derivatives-user exception, so it is excepted from the VaR tests; the ratio below is informational, not the operative limit.
Rule 18f-4(c)(4): a fund whose derivatives exposure (gross notional, including the value of assets sold short) is <= 10% of net assets is excepted from the VaR tests and the full derivatives risk management program.
No confidence interval: this follows from portfolio construction, not from an estimate.
Rule 18f-4(c)(2)(i): fund VaR at 99% over 20 trading days must not exceed 200% of the designated reference portfolio's VaR on the same basis.
Informational — does not governThis fund is excepted from the VaR tests, so the ratio below is context rather than the operative limit. It is shown because it is still a description of the book’s risk, not because it decides anything.
historical method · 335 monthly observations · about 3.4 in the 99% tail · paired percentile bootstrap over months
The estimators agree, which is mild evidence the number isn’t an artefact of one method.
Engineering approximation of SEC Rule 18f-4 for research display. Not a compliance opinion and not a determination that any fund is compliant. Hypothetical model portfolio, not a registered fund.
The research long-short construction behind this factor does not qualify for this exception — a dollar-neutral book counts its full short notional, which is 100% of net assets against a 10% threshold. This product sidesteps that by holding the long leg alone, which is also why the long-leg Sharpe is reported separately throughout the site.
See the long-short verdict on the factor page →Did the edge survive the paper coming out?
Split at January of the year after the factor was published. The post-publication stretch IS genuinely out-of-sample relative to the original study -- the predictor was public by then -- so it speaks to whether the effect survived being known. Nothing is fitted here, so this is performance SINCE PUBLICATION, not validation of a model. Note the 'pre' side is our data before publication (our panel starts ~1999), NOT the study's original in-sample period, which usually ran decades earlier; a decay figure compares before-vs-after within our sample and is not a comparison against the published result.
Is this record broadly durable, or one regime?
3-year rolling windows, stepping 1 year (26 windows). Dispersion is the spread of window Sharpes — higher means the record depends more on which era you look at.
Rules-based factors fit no parameters, so these windows are not out-of-sample tests and do not validate a fitted model. They show whether the factor's record is consistent across eras or driven by one regime.
Long leg is what this fund holds — long-short is shown for reference
| Period | Long leg | Long-short |
|---|---|---|
| 1 yearcum. | 36.6% | 16.3% |
| 3 yearsp.a. | 24.9% | 0.1% |
| 5 yearsp.a. | 9.4% | 3.8% |
| 10 yearsp.a. | 10.6% | -1.4% |
| Since inceptionp.a. | 7.9% | -1.0% |
| Year | Long leg | Long-short |
|---|---|---|
| 202611 mo | 34.9% | 13.3% |
| 2025 | 24.5% | -4.4% |
| 2024 | 2.1% | -14.5% |
| 2023 | -3.2% | -10.6% |
| 2022 | -12.2% | 28.2% |
| 2021 | 8.2% | -1.4% |
| 2020 | 18.1% | -10.0% |
| 2019 | 18.7% | -1.5% |
| 2018 | 3.1% | -8.4% |
| 2017 | 19.6% | 0.6% |
| 2016 | -3.3% | 3.4% |
| 2015 | 9.9% | -7.9% |
| 2014 | 16.8% | -7.6% |
| 2013 | 31.7% | -4.6% |
| 2012 | 20.2% | 1.3% |
| 2011 | 17.2% | 19.3% |
| 2010 | 13.5% | 3.1% |
| 2009 | 12.7% | -2.5% |
| 2008 | -22.8% | -11.0% |
| 2007 | 6.3% | -3.1% |
| 2006 | 10.1% | 13.4% |
| 2005 | 9.6% | -9.3% |
| 2004 | -19.3% | -19.4% |
| 2003 | 42.7% | 6.7% |
| 2002 | -25.4% | 6.7% |
| 2001 | -5.3% | 25.2% |
| 2000 | 22.1% | -30.9% |
| 1999 | 6.0% | 21.8% |
Long leg = the top bucket this fund holds; long-short additionally shorts the bottom bucket and is not achievable in a long-only vehicle. Trailing figures run through November 2026: 1 year is a plain cumulative 12-month return (cum.), 3 years and longer are annualised (p.a.). Years marked with a month count are partial. These match the fact sheet’s tables by construction. Hypothetical backtest, gross of the placeholder expense ratio and trading costs — not investor results.
The Foundry Healthcare InvestPPEInv Factor ETF tracks a rules-based model that ranks Healthcare common stocks each month by a InvestPPEInv signal and holds the top quintile with the lowest values. Signals are computed from point-in-time Sharadar fundamentals and total-return prices. The portfolio reconstitutes monthly and is cap-weighted within the long leg.
This is a hypothetical model portfolio for research display only — not a registered fund, not an offer, and not investment advice.
Auto-generated from the model’s metrics and current holdings. Every document is labeled DRAFT / hypothetical.
Objective, fees, strategy, and key risks.
Full strategy, model methodology, and risks.
Policies, construction, and governance.
One-page snapshot with top holdings.
Full current constituent list.
DRAFT — HYPOTHETICAL MODEL PORTFOLIO — NOT A REGISTERED FUND, NOT AN OFFER TO SELL SECURITIES, NOT INVESTMENT ADVICE.